We are live on ! Find out more
Barclays

Barclays Portfolio holdings

AUM $416B
1-Year Est. Return 33.63%
 

Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.

This Fund
S&P 500
This Quarter Est. Return
+13.33%
1 Year Est. Return
+33.63%
3 Year Est. Return
+104.86%
5 Year Est. Return
+133.18%
10 Year Est. Return
+529.74%
AUM
$273B
AUM Growth
+$112B
Cap. Flow
+$85.1B
Cap. Flow %
31.22%
Top 10 Hldgs %
26.87%
Holding
5,469
New
899
Increased
2,915
Reduced
940
Closed
253

Sector Composition

Rank Sector Weight
1 Technology 20.95%
2 Financials 8.18%
3 Consumer Discretionary 7.81%
4 Healthcare 7.12%
5 Communication Services 6.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BMR icon
4976
Beamr Imaging
BMR
$20M
$252 ﹤0.01%
174
-26
-13% -$34
HHLA.WS
4977
DELISTED
HH&L Acquisition Co. Redeemable warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50
HHLA.WS
$250 ﹤0.01%
10,000
LIDR icon
4978
AEye
LIDR
$58.4M
$238 ﹤0.01%
+104
New +$511
AONC
4979
DELISTED
American Oncology Network, Inc. Class A Common Stock
AONC
$224 ﹤0.01%
+38
New +$246
EACPW
4980
DELISTED
Edify Acquisition Corp. Warrant
EACPW
$202 ﹤0.01%
14,000
AGQ icon
4981
ProShares Ultra Silver
AGQ
$1.29B
$190 ﹤0.01%
7
-7
-50% -$185
CBIO
4982
Crescent Biopharma
CBIO
$586M
$179 ﹤0.01%
1
-1
-50% -$155
DMTK
4983
DELISTED
DermTech, Inc. Common Stock
DMTK
$170 ﹤0.01%
97
-97
-50% -$142
BPT
4984
DELISTED
BP Prudhoe Bay Royalty Trust
BPT
$165 ﹤0.01%
67
-67
-50% -$272
GMAB icon
4985
Genmab
GMAB
$18B
$159 ﹤0.01%
5
-5
-50% -$157
BOLT icon
4986
Bolt Biotherapeutics
BOLT
$7.59M
$156 ﹤0.01%
7
MNTS icon
4987
Momentus
MNTS
$79.9M
0
CORN icon
4988
Teucrium Corn Fund
CORN
$168M
$151 ﹤0.01%
7
-7
-50% -$155
TXMD icon
4989
TherapeuticsMD
TXMD
$24M
$142 ﹤0.01%
+63
New +$152
HIMX
4990
Himax Technologies
HIMX
$2.33B
$127 ﹤0.01%
21
-1,021
-98% -$5.89K
JDST icon
4991
Direxion Daily Junior Gold Miners Index Bear 2X ETF
JDST
$23.5M
0
PDYN icon
4992
Palladyne AI
PDYN
$282M
$120 ﹤0.01%
166
DYAI icon
4993
Dyadic International
DYAI
$35.3M
$116 ﹤0.01%
72
SRS icon
4994
ProShares UltraShort Real Estate
SRS
$15.2M
$114 ﹤0.01%
2
-2
-50% -$149
QNCX icon
4995
Quince Therapeutics
QNCX
$28.2M
$105 ﹤0.01%
1
NUVB.WS
4996
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$98 ﹤0.01%
1,638
VST.WS.A
4997
DELISTED
Vistra Corp.Warrants to purchase Common Stock (Expiring February 2, 2024)
VST.WS.A
$93 ﹤0.01%
12,758
GOSS icon
4998
Gossamer Bio
GOSS
$86.9M
$91 ﹤0.01%
100
-100
-50% -$74
MREO
4999
Mereo BioPharma
MREO
$48.4M
$88 ﹤0.01%
38
-38
-50% -$73
TMQ
5000
Trilogy Metals
TMQ
$608M
$86 ﹤0.01%
200

Similar funds

Barclays's Q4 2023 Portfolio in Review

As of Q4 2023, Barclays held 5,469 positions worth $273B, up 70% from $161B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Barclays deployed $85.1B of net new capital in Q4 2023, opening 899 new positions and adding to 2,915 existing holdings. Its largest new stake was AngloGold Ashanti: 9,667,894 shares worth $181M.

By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 27% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was CRH, an estimated $673M trimmed.

  • Barclays's largest Q4 2023 buy was AngloGold Ashanti: 9,667,894 shares worth $181M.
  • Barclays added most to Meta Platforms (Facebook) in Q4 2023, an estimated $1.51B increase.
  • Barclays's biggest Q4 2023 reduction was CRH, cutting an estimated $673M.
  • Barclays fully exited Activision Blizzard in Q4 2023, selling an estimated $417M.
  • Barclays's ten largest holdings make up 27% of its $273B portfolio in Q4 2023.
  • Barclays opened 899 new positions and closed 253 in Q4 2023.
  • Barclays's portfolio value rose 70% quarter-over-quarter to $273B.

Based on Barclays's 13F filing for Q4 2023, filed 15 Feb 2024.